## **Core Concept**
The patient's condition described is consistent with leprosy, specifically paucibacillary leprosy given the treatment regimen of paucibacillary multidrug therapy (PB-MDT). Leprosy, also known as Hansen's disease, is a chronic infection caused by *Mycobacterium leprae*, primarily affecting the skin, peripheral nerves, mucosa of the upper respiratory tract, and eyes. The treatment of leprosy involves multidrug therapy to prevent resistance.

## **Why the Correct Answer is Right**
The World Health Organization (WHO) recommends a 6-month course of PB-MDT for paucibacillary leprosy, which includes rifampicin, dapsone, and clofazimine. If, at the end of the treatment, there is persistent erythema and induration in the plaques, it indicates an inflammatory reaction, possibly Type 1 lepra reaction or reversal reaction. The WHO recommends that such reactions be managed with corticosteroids. The continuation of MDT is not required if the patient has completed the recommended course, but managing the reaction is crucial to prevent nerve damage.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because simply continuing the same treatment without addressing the reaction might not be sufficient and could potentially lead to further complications.
- **Option B:** This option might seem plausible but changing to multibacillary MDT (MB-MDT) is not indicated solely based on the presence of a Type 1 reaction; the classification of leprosy as multibacillary or paucibacillary is based on clinical and bacteriological criteria.
- **Option C:** Stopping treatment and not addressing the reaction could lead to progression of the disease and nerve damage.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that Type 1 lepra reactions, which present with erythema and induration of existing skin lesions, are managed with corticosteroids to prevent nerve damage. Prompt recognition and management of these reactions are critical to prevent long-term disability.

## **Correct Answer:** D.